

# Stephen E Spurgeon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2376540/publications.pdf>

Version: 2024-02-01

30  
papers

877  
citations

623734

14  
h-index

477307

29  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1442  
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2023, 64, 722-724.	1.3	1
2	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
3	Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia. <i>Case Reports in Hematology</i> , 2022, 2022, 1-5.	0.4	5
4	Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 1207-1211.	5.2	12
5	Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA7502-LBA7502.	1.6	6
6	A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2021, 106, 294-297.	2.2	2
7	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 716-721.	1.3	3
8	The First Report of Endoscopic Ultrasound-guided Intralesional Rituximab in a Patient With Mantle Cell Lymphoma Presenting With Isolated Colorectal Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e485-e487.	0.4	0
9	Phase 1â€² study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed Bâ€²cell nonâ€²Hodgkin lymphoma and previously untreated mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 845-854.	2.5	18
10	Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2258-2260.	1.3	6
11	Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. <i>Oncotarget</i> , 2018, 9, 24576-24589.	1.8	36
12	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw263.	6.3	10
13	CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. <i>Leukemia Research</i> , 2017, 53, 39-49.	0.8	22
14	Concurrent STAT3, DNMT3A, and TET2 mutations in Tâ€²CLL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential. <i>American Journal of Hematology</i> , 2017, 92, E6-E8.	4.1	16
15	Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. <i>American Journal of Case Reports</i> , 2017, 18, 516-519.	0.8	3
16	Targeting BCL-2 and ABL/LYN in Philadelphia chromosomeâ€²positive acute lymphoblastic leukemia. <i>Science Translational Medicine</i> , 2016, 8, 354ra114.	12.4	65
17	Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome. <i>Leukemia Research Reports</i> , 2015, 4, 8-11.	0.4	6
18	MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting. <i>Annals of Hematology</i> , 2015, 94, 1941-1944.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Aberrations of MYC Are a Common Event in B-Cell Prolymphocytic Leukemia. American Journal of Clinical Pathology, 2014, 142, 347-354.	0.7	40
20	Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event. Cancer Genetics, 2014, 207, 340-343.	0.4	6
21	A phase 1 study of the PI3K $\hat{\nu}$ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood, 2014, 123, 3398-3405.	1.4	245
22	The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 378-387.	2.5	40
23	Improved survival in hairy cell leukaemia over three decades: a <scp>SEER</scp> database analysis of prognostic factors. British Journal of Haematology, 2013, 163, 407-409.	2.5	32
24	Combined Epigenetic and Immunotherapy For Newly Diagnosed Mantle Cell Lymphoma: Correlative Studies Suggest The Importance Of Enhanced ADCC, Mechanisms of Resistance and Cyclin D1 Nuclear Localization Genotype. Blood, 2013, 122, 3063-3063.	1.4	3
25	Survival trends in mantle cell lymphoma in the United States over 16 years 1992â€“2007. Leukemia and Lymphoma, 2012, 53, 1488-1493.	1.3	73
26	Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leukemia and Lymphoma, 2011, 52, 1488-1494.	1.3	39
27	A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma. Blood, 2011, 118, 441-441.	1.4	4
28	Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 $\hat{\nu}$ , In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood, 2010, 116, 1777-1777.	1.4	54
29	Cladribine: not just another purine analogue?. Expert Opinion on Investigational Drugs, 2009, 18, 1169-1181.	4.1	51
30	Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110 $\hat{\nu}$ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.. Blood, 2009, 114, 922-922.	1.4	24